Cancer Genetics, Inc. to Present at The Pioneers 2017 Conference Presented by Joseph Gunnar & Co., LLC
April 25 2017 - 7:00AM
Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or “The Company”), a
leader in enabling precision medicine for oncology through
molecular markers and diagnostics, announced today that Panna
Sharma, President and CEO, will present a corporate overview at the
Pioneers 2017 Conference presented by Joseph Gunnar & Co., LLC
on Tuesday, May 2, 2017 at 9:00 AM Eastern Time, at the Mandarin
Oriental Hotel in New York City.
Investors and interested parties may listen to
the live webcast of this presentation by clicking here.
For additional information on the conference,
including registration and company participation, please click
here.
About Cancer Genetics, Inc.Cancer Genetics,
Inc. is an emerging leader in enabling precision medicine for
oncology through the use of molecular markers and information. CGI
is developing a global footprint with locations in the US, India
and China. It has established strong clinical research
collaborations with major cancer centers such as Memorial Sloan
Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of
Medicine at USC and the National Cancer Institute.
The Company offers a comprehensive range of laboratory services
that provide critical genomic and biomarker information. Its
state-of-the-art reference labs are CLIA-certified and
CAP-accredited in the US and have licensure from several states
including New York State.
For more information, please visit or follow
us:
Internet: www.cancergenetics.com
Twitter: @Cancer_Genetics
Facebook: www.facebook.com/CancerGenetics
Forward-Looking Statements:This press release
may contain forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. All statements
pertaining to future financial and/or operating results, future
growth in revenues, margins, research, technology, clinical
development and potential opportunities for Cancer Genetics, Inc.
tests and services, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management constitute forward-looking statements.
Any statements that are not historical fact (including, but not
limited to, statements that contain words such as "will,"
"believes," "plans," "anticipates," "expects," "estimates") should
also be considered to be forward-looking statements.
Forward-looking statements involve risks and uncertainties,
including, without limitation, risks inherent in the discovery,
development and/or commercialization of potential therapies or
products, risks of cancellation of customer contracts or
discontinuance of trials, risks that anticipated benefits from
acquisitions will not be realized, uncertainty in the results of
clinical trials or regulatory approvals, need and ability to obtain
future capital, maintenance of intellectual property rights and
other risks discussed in the Cancer Genetics, Inc. Form 10-K for
the year ended December 31, 2016 along with other filings with the
Securities and Exchange Commission. These forward-looking
statements speak only as of the date hereof. Cancer Genetics, Inc.
disclaims any obligation to update these forward-looking
statements.
MEDIA CONTACT:
Panna Sharma
Cancer Genetics, Inc.
Tel: 201-528-9200
Email: panna.sharma@cgix.com
INVESTOR RELATIONS CONTACT:
Richard Moyer
Cameron Associates
535 Fifth Ave., New York, NY 10017
Tel: 212-554-5466
Email: richard@cameronassoc.com
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Apr 2023 to Apr 2024